{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:54:16Z","timestamp":1784735656379,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011621","name":"Winship Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["ZIADC-DC000090"],"award-info":[{"award-number":["ZIADC-DC000090"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["ZIADC-DC000090"],"award-info":[{"award-number":["ZIADC-DC000090"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["ZIADC-DC000090"],"award-info":[{"award-number":["ZIADC-DC000090"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Institute, United States","award":["P30CA138292"],"award-info":[{"award-number":["P30CA138292"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The antigen processing machinery (APM) components needed for a tumor cell to present an antigen to a T cell are expressed at low levels in solid tumors, constituting an important mechanism of immune escape. More than most other solid tumors, head and neck squamous cell carcinoma (HNSCC) cells tend to have low APM expression, rendering them insensitive to immune checkpoint blockade and most other forms of immunotherapy. In HNSCC, this APM deficiency is largely driven by high levels of EGFR and SHP2, leading to low expression and activation of STAT1; however, recent studies suggest that p53, which is often mutated in HNSCCs, may also play a role. In the current study, we aimed to investigate the extent to which STAT1 and p53 individually regulate APM component expression in HNSCC cells. We found that in cells lacking functional p53, APM expression could still be induced by interferon-gamma or DNA-damaging chemotherapy (cisplatin) as long as STAT1 expression remained intact; when both transcription factors were knocked down, APM component expression was abolished. When we bypassed these deficient pathways by rescuing the expression of NLRC5, APM expression was also restored. These results suggest that dual loss of functional STAT1 and p53 may render HNSCC cells incapable of processing and presenting antigens, but rescue of downstream NLRC5 expression may be an attractive strategy for restoring sensitivity to T cell-based immunotherapy.<\/jats:p>","DOI":"10.1007\/s00262-023-03589-y","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T12:02:16Z","timestamp":1705492936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rescue of NLRC5 expression restores antigen processing machinery in head and neck cancer cells lacking functional STAT1 and p53"],"prefix":"10.1007","volume":"73","author":[{"given":"Brendan L. C.","family":"Kinney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasulu","family":"Gunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Kansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J.","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil F.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Katherine","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel A.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"3589_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet 394:1915\u20131928","journal-title":"The Lancet"},{"key":"3589_CR2","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1158\/1078-0432.CCR-05-2750","volume":"12","author":"RL Ferris","year":"2006","unstructured":"Ferris RL, Whiteside TL, Ferrone S (2006) Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 12:3890\u20133895","journal-title":"Clin Cancer Res"},{"key":"3589_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00262-010-0961-7","volume":"60","author":"MS Leibowitz","year":"2011","unstructured":"Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL (2011) Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother 60:525\u2013535","journal-title":"Cancer Immunol Immunother"},{"key":"3589_CR4","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/1078-0432.CCR-12-1517","volume":"19","author":"MS Leibowitz","year":"2013","unstructured":"Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR et al (2013) SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res 19:798\u2013808","journal-title":"Clin Cancer Res"},{"key":"3589_CR5","doi-asserted-by":"publisher","first-page":"e002899","DOI":"10.1136\/jitc-2021-002899","volume":"9","author":"A Hazini","year":"2021","unstructured":"Hazini A, Fisher K, Seymour L (2021) Deregulation of HLA-I in cancer and its central importance for immunotherapy. J Immunother Cancer 9:e002899","journal-title":"J Immunother Cancer"},{"key":"3589_CR6","doi-asserted-by":"publisher","first-page":"eabb0152","DOI":"10.1126\/scitranslmed.abb0152","volume":"12","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Tariveranmoshabad M, Hakimi K, Kremer S, Campbell KM, Funes JM et al (2020) Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Sci Transl Med 12:eabb0152","journal-title":"Sci Transl Med"},{"key":"3589_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A (2020) Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 20:25\u201339","journal-title":"Nat Rev Immunol"},{"key":"3589_CR8","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1158\/1535-7163.MCT-15-0305","volume":"14","author":"NC Schmitt","year":"2015","unstructured":"Schmitt NC, Trivedi S, Ferris RL (2015) STAT1 activation is enhanced by cisplatin and variably affected by EGFR inhibition in HNSCC cells. Mol Cancer Ther 14:2103\u20132111","journal-title":"Mol Cancer Ther"},{"key":"3589_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.oraloncology.2019.06.016","volume":"95","author":"SJ Park","year":"2019","unstructured":"Park SJ, Ye W, Xiao R, Silvin C, Padget M, Hodge JW et al (2019) Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Oral Oncol 95:127\u2013135","journal-title":"Oral Oncol"},{"key":"3589_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-17-0235","volume":"5","author":"L Tran","year":"2017","unstructured":"Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ et al (2017) Cisplatin alters antitumor immunity and synergizes with PD-1\/PD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol Res 5:1141\u20131151","journal-title":"Cancer Immunol Res"},{"key":"3589_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/hed.10274","volume":"25","author":"CR Bradford","year":"2003","unstructured":"Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A et al (2003) P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25:654\u2013661","journal-title":"Head Neck"},{"key":"3589_CR12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/sj.cdd.4402270","volume":"15","author":"I Youlyouz-Marfak","year":"2008","unstructured":"Youlyouz-Marfak I, Gachard N, Le Clorennec C, Najjar I, Baran-Marszak F, Reminieras L et al (2008) Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ 15:376\u2013385","journal-title":"Cell Death Differ"},{"key":"3589_CR13","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/jcb.25592","volume":"117","author":"G Zhou","year":"2016","unstructured":"Zhou G, Liu Z, Myers JN (2016) TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response. J Cell Biochem 117:2682\u20132692","journal-title":"J Cell Biochem"},{"key":"3589_CR14","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3390\/cancers15041029","volume":"15","author":"T Toni","year":"2023","unstructured":"Toni T, Viswanathan R, Robbins Y, Gunti S, Yang X, Huynh A et al (2023) Combined inhibition of IAPs and WEE1 enhances TNFalpha- and radiation-induced cell death in head and neck squamous carcinoma. Cancers (Basel) 15:1029","journal-title":"Cancers (Basel)"},{"key":"3589_CR15","doi-asserted-by":"publisher","first-page":"1710398","DOI":"10.1080\/2162402X.2019.1710398","volume":"9","author":"W Ye","year":"2020","unstructured":"Ye W, Gunti S, Allen CT, Hong Y, Clavijo PE, Van Waes C et al (2020) ASTX660, an antagonist of cIAP1\/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. Oncoimmunology 9:1710398","journal-title":"Oncoimmunology"},{"key":"3589_CR16","doi-asserted-by":"publisher","first-page":"e005940","DOI":"10.1136\/jitc-2022-005940","volume":"11","author":"V Kansal","year":"2023","unstructured":"Kansal V, Burnham AJ, Kinney BLC, Saba NF, Paulos C, Lesinski GB et al (2023) Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. J Immunother Cancer 11:e005940","journal-title":"J Immunother Cancer"},{"key":"3589_CR17","doi-asserted-by":"publisher","first-page":"26223","DOI":"10.1074\/jbc.M110.109736","volume":"285","author":"A Neerincx","year":"2010","unstructured":"Neerincx A, Lautz K, Menning M, Kremmer E, Zigrino P, Hosel M et al (2010) A role for the human nucleotide-binding domain, leucine-rich repeat-containing family member NLRC5 in antiviral responses. J Biol Chem 285:26223\u201326232","journal-title":"J Biol Chem"},{"key":"3589_CR18","unstructured":"Institute B. Depmap Portal. https:\/\/depmap.org\/portal\/cell_line\/ACH-002251?tab=mutations. Accessed on October 15, 2023."},{"key":"3589_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA et al (2017) Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 19:1189\u20131201","journal-title":"Cell Rep"},{"key":"3589_CR20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.ymthe.2021.11.011","volume":"30","author":"TE Bickett","year":"2022","unstructured":"Bickett TE, Knitz MW, Piper M, Oweida AJ, Gadwa J, Darragh LB et al (2022) Dichotomous effects of cellular expression of STAT3 on tumor growth of HNSCC. Mol Ther 30:1149\u20131162","journal-title":"Mol Ther"},{"key":"3589_CR21","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/jnci\/djz036","volume":"111","author":"AJ Oweida","year":"2019","unstructured":"Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A et al (2019) STAT3 Modulation of regulatory T cells in response to radiation therapy in head and neck cancer. J Natl Cancer Inst 111:1339\u20131349","journal-title":"J Natl Cancer Inst"},{"key":"3589_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.oraloncology.2019.06.004","volume":"95","author":"LM Zhong","year":"2019","unstructured":"Zhong LM, Liu ZG, Zhou X, Song SH, Weng GY, Wen Y et al (2019) Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma. Oral Oncol 95:157\u2013163","journal-title":"Oral Oncol"},{"key":"3589_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fimmu.2017.00150","volume":"8","author":"S Benko","year":"2017","unstructured":"Benko S, Kovacs EG, Hezel F, Kufer TA (2017) NLRC5 functions beyond MHC I regulation-What do we know so far? Front Immunol 8:150","journal-title":"Front Immunol"},{"key":"3589_CR24","doi-asserted-by":"publisher","first-page":"5999","DOI":"10.1073\/pnas.1602069113","volume":"113","author":"S Yoshihama","year":"2016","unstructured":"Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B et al (2016) NLRC5\/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A 113:5999\u20136004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3589_CR25","doi-asserted-by":"publisher","first-page":"692","DOI":"10.21037\/tcr.2016.11.76","volume":"5","author":"MW Braun","year":"2016","unstructured":"Braun MW, Iwakuma T (2016) Regulation of cytotoxic T-cell responses by p53 in cancer. Transl Cancer Res 5:692\u2013697","journal-title":"Transl Cancer Res"},{"key":"3589_CR26","doi-asserted-by":"publisher","first-page":"7740","DOI":"10.1038\/sj.onc.1203235","volume":"18","author":"K Zhu","year":"1999","unstructured":"Zhu K, Wang J, Zhu J, Jiang J, Shou J, Chen X (1999) p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene 18:7740\u20137747","journal-title":"Oncogene"},{"key":"3589_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1404216","volume":"7","author":"EC Moore","year":"2018","unstructured":"Moore EC, Sun L, Clavijo PE, Friedman J, Harford JB, Saleh AD et al (2018) Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms. Oncoimmunology 7:e1404216","journal-title":"Oncoimmunology"},{"key":"3589_CR28","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","volume":"24","author":"J Biton","year":"2018","unstructured":"Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau J et al (2018) TP53, STK11, and EGFR mutations predict tumor immune profile and the response to Anti-PD-1 in lung adenocarcinoma. Clin Cancer Res 24:5710\u20135723","journal-title":"Clin Cancer Res"},{"key":"3589_CR29","doi-asserted-by":"publisher","first-page":"aar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J et al (2018) Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362:aar3593","journal-title":"Science"},{"key":"3589_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.oraloncology.2015.11.022","volume":"56","author":"JL Geiger","year":"2016","unstructured":"Geiger JL, Grandis JR, Bauman JE (2016) The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations. Oral Oncol 56:84\u201392","journal-title":"Oral Oncol"},{"key":"3589_CR31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3892\/or.2013.2455","volume":"30","author":"TG De Carvalho","year":"2013","unstructured":"De Carvalho TG, De Carvalho AC, Maia DC, Ogawa JK, Carvalho AL, Vettore AL (2013) Search for mutations in signaling pathways in head and neck squamous cell carcinoma. Oncol Rep 30:334\u2013340","journal-title":"Oncol Rep"},{"key":"3589_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.oraloncology.2019.06.032","volume":"96","author":"V Saloura","year":"2019","unstructured":"Saloura V, Izumchenko E, Zuo Z, Bao R, Korzinkin M, Ozerov I et al (2019) Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncol 96:77\u201388","journal-title":"Oral Oncol"},{"key":"3589_CR33","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517:576\u201382.","DOI":"10.1038\/nature14129"},{"key":"3589_CR34","doi-asserted-by":"publisher","first-page":"11146","DOI":"10.1158\/0008-5472.CAN-05-0772","volume":"65","author":"A Albers","year":"2005","unstructured":"Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C et al (2005) Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65:11146\u201311155","journal-title":"Cancer Res"},{"key":"3589_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0168-1702(02)00123-5","volume":"88","author":"PM O'Brien","year":"2002","unstructured":"O\u2019Brien PM, Saveria CM (2002) Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res 88:103\u2013117","journal-title":"Virus Res"},{"key":"3589_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nrc700","volume":"2","author":"RW Tindle","year":"2002","unstructured":"Tindle RW (2002) Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2:59\u201365","journal-title":"Nat Rev Cancer"},{"key":"3589_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1006\/clim.2001.5094","volume":"101","author":"A Vambutas","year":"2001","unstructured":"Vambutas A, DeVoti J, Pinn W, Steinberg BM, Bonagura VR (2001) Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol 101:94\u201399","journal-title":"Clin Immunol"},{"key":"3589_CR38","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27254","volume":"3","author":"EV King","year":"2014","unstructured":"King EV, Ottensmeier CH, Thomas GJ (2014) The immune response in HPV oropharyngeal cancer. Oncoimmunology 3:e27254","journal-title":"Oncoimmunology"},{"key":"3589_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112508","volume":"42","author":"S Miyauchi","year":"2023","unstructured":"Miyauchi S, Kim SS, Jones RN, Zhang L, Guram K, Sharma S et al (2023) Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway. Cell Rep 42:112508","journal-title":"Cell Rep"},{"key":"3589_CR40","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/cancers11081129","volume":"11","author":"SF Gameiro","year":"2019","unstructured":"Gameiro SF, Ghasemi F, Barrett JW, Nichols AC, Mymryk JS (2019) High level expression of MHC-II in HPV+ head and neck cancers suggests that tumor epithelial cells serve an important role as accessory antigen presenting cells. Cancers (Basel) 11:1129","journal-title":"Cancers (Basel)"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03589-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03589-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03589-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T13:05:51Z","timestamp":1707570351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03589-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3589"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03589-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"28 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NCS declares consulting for Sensorion, Checkpoint Surgical, Synergy Research, Inc., and Regeneron; and research funding from Astex Pharmaceuticals, Inc. (unrelated to this work).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Schmitt \u2013 <i>Consulting:<\/i> Checkpoint Surgical, Sensorion, Synergy Research, Regeneron. <i>Book Royalties:<\/i> Plural Publishing. <i>Clinical Trial Funding:<\/i> Astex Pharmaceuticals","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure Statements"}}],"article-number":"10"}}